Dr Annalisa Jenkins MBBS FRCP is a life sciences thought leader with over 25 years’ experience building and financing companies pursuing cures for the most challenging diseases globally. She has consistently mentored leadership teams advancing programmes from basic research through clinical development, regulatory approval and into healthcare systems globally.
Dr Jenkins graduated in Medicine at the University of London and received her Fellowship of the Royal College of Physicians London. She trained in cardiovascular medicine and was a research fellow at Imperial College.
Earlier in her career, Dr Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of Surgeon Lieutenant Commander. Over 15 years, she also held senior leadership roles at Merck Serono and Bristol Myers-Squibb. She served as President and CEO of Dimension Therapeutics, a leading gene therapy company she took public on the NASDAQ and subsequently sold to Ultragenyx.
Following her relocation back to the UK, Dr Jenkins developed a portfolio of roles spanning the public, private and charitable sectors, including Genomics England, The King's Fund, British Heart Foundation and Chair of YouBelong, a leading mental health care charity. She serves as a Science Board Committee Member to the US Food & Drug Administration (FDA), which advises FDA leadership on complex issues, and is Chair of the Court for The London School of Hygiene and Tropical Medicine. She is also a board member of several growing public and private companies including Oncimmune, AVROBIO, COMPASS Pathways and Affimed.
Dr Jenkins serves on a number of advisory boards and contributes publicly on leadership with purpose, social entrepreneurship, diversity and innovation.